On the morning of April 26, Binh Dinh Pharmaceutical and Medical Equipments Joint Stock Company (BIDIPHAR – HOSE:DBD) successfully convened its 2025 Annual General Meeting. The meeting saw shareholders approve key resolutions, including the 2025 business plan targeting a charter capital increase to VND1,134 billion, revenue of VND2,000 billion, and pre-tax profit of VND335 billion. Additionally, a 20% cash dividend payout for 2024 was approved.
The meeting took place in a formal atmosphere, attended by the full Board of Directors, Supervisory Board, Management Board, and a large number of shareholders and their representatives. It provided an opportunity for shareholders to hear direct reports from the leadership on Bidiphar’s performance in the past year and plans for the year ahead.
In 2024, Bidiphar reported positive business results despite economic volatility. The company achieved a 5% revenue increase compared to 2023, reaching VND1,817 billion (91% of the annual target), and a 2% profit growth, amounting to VND325 billion.
Speaking at the meeting, Mr. Tạ Nam Bình, Chairman of Bidiphar’s Board of Directors, stated, “2024 marked 45 years of Bidiphar’s establishment and growth. With a solid foundation built over decades, we are confident in entering a new development phase, with strong investments in technology and infrastructure while enhancing our competitiveness in the domestic pharmaceutical market.”
Looking to 2025, despite anticipating domestic and global challenges, Bidiphar set higher growth targets. The company aims to achieve a charter capital of VND1,134 billion, revenue of VND2,000 billion, and pre-tax profit of VND335 billion. This ambition is underpinned by a strategy to leverage competitive advantages, expand market share, and boost revenue from key product lines such as oncology drugs, dialysis solutions, and antibiotics. Bidiphar also plans to broaden its distribution channels, including hospitals, pharmacies, pharmacy chains, e-commerce, and exports. Notably, the company is accelerating efforts to expand exports to Southeast Asia and Africa while pursuing approvals to enter the stringent European market.
Ms. Phạm Thị Thanh Hương, Bidiphar’s General Director, shared the company’s development strategy, saying, “2025 will be a pivotal year for Bidiphar’s 2025-2030 strategy. We are investing heavily in research and development, focusing on high-tech products, particularly oncology drugs and other specialized treatments, where Bidiphar has established expertise and market recognition.”
Bidiphar is prioritizing research and development of new and improved products to meet evolving customer and market demands, reinforcing its competitive edge with quality as the cornerstone. The company will also optimize operations through innovative programs and cost-effective approaches.
For 2025 investments, Bidiphar will allocate over VND570 billion to its small-volume sterile drug manufacturing plant, a flagship project aimed at enhancing production capacity for high-quality injectable drugs meeting international standards. Additionally, the company will invest in digital transformation, production, research, and the construction of an office building at 34 Ngô Mây.
The 2025 AGM approved a 20% cash dividend for 2024, ensuring maximum benefits for shareholders while securing capital for future development projects. Beyond business matters, the meeting also endorsed Bidiphar’s 2025 corporate social responsibility (CSR) plan. The company will continue community healthcare initiatives, including free health consultations and medical services in remote areas, as well as scholarships for pharmaceutical students. Bidiphar remains committed to environmental protection and sustainable development, reinforcing its image as a socially responsible pharmaceutical enterprise.
With its 2024 achievements and a clear roadmap for 2025, Bidiphar solidifies its position as a leading pharmaceutical company in Vietnam, dedicated to improving product and service quality to meet the growing healthcare needs of the population.
